{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:55:53Z","timestamp":1789624553261,"version":"build-2803163510"},"reference-count":198,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04822-4","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:50:42Z","timestamp":1758963042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Non-oncologic to oncologic drug: A systematic review of drug repurposing in cancer"],"prefix":"10.1007","volume":"95","author":[{"given":"Yarava","family":"Dhanush","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vakkalagadda Siva","family":"Ganesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"key":"4822_CR1","first-page":"e2023225","volume":"94","author":"C Renzi","year":"2023","unstructured":"Renzi C, Odelli S, Morani F, Majano SB, Signorelli C (2023) Delays in cancer diagnosis: challenges and opportunities in Europe. Acta Biomed 94:e2023225","journal-title":"Acta Biomed"},{"key":"4822_CR2","doi-asserted-by":"publisher","first-page":"2161423","DOI":"10.1080\/19490976.2023.2269623","volume":"15","author":"K Mima","year":"2023","unstructured":"Mima K, Hamada T, Inamura K, Baba H, Ugai T, Ogino S (2023) The Microbiome and rise of early-onset cancers: knowledge gaps and research opportunities. Gut Microbes 15:2161423","journal-title":"Gut Microbes"},{"key":"4822_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.gendis.2022.12.013","volume":"11","author":"D Ajmeera","year":"2024","unstructured":"Ajmeera D, Ajumeera R (2024) Drug repurposing: a novel strategy to target cancer stem cells and therapeutic resistance. Genes Dis 11:148\u2013175","journal-title":"Genes Dis"},{"key":"4822_CR4","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/bjc.2014.598","volume":"112","author":"Z Wang","year":"2015","unstructured":"Wang Z, McLoone P, Morrison DS (2015) Diet, exercise, obesity, smoking and alcohol consumption in cancer survivors and the general population: a comparative study of 16 282 individuals. Br J Cancer 112:572\u2013575","journal-title":"Br J Cancer"},{"key":"4822_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1475-2891-3-19","volume":"3","author":"MS Donaldson","year":"2004","unstructured":"Donaldson MS (2004) Nutrition and cancer: a review of the evidence for an anti-cancer diet. Nutr J 3:19","journal-title":"Nutr J"},{"key":"4822_CR6","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.jnutbio.2013.02.009","volume":"24","author":"B Ruiz-N\u00fa\u00f1ez","year":"2013","unstructured":"Ruiz-N\u00fa\u00f1ez B, Pruimboom L, Dijck-Brouwer DAJ, Muskiet FAJ (2013) Lifestyle and nutritional imbalances associated with Western diseases: causes and consequences of chronic systemic low-grade inflammation in an evolutionary context. J Nutr Biochem 24:1183\u20131201","journal-title":"J Nutr Biochem"},{"key":"4822_CR7","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.canep.2015.03.017","volume":"39","author":"C Espina","year":"2015","unstructured":"Espina C, Straif K, Friis S, Kogevinas M, Saracci R, Vainio H et al (2015) European code against cancer 4th edition: Environment, occupation and cancer. Cancer Epidemiol 39:S84\u2013S92","journal-title":"Cancer Epidemiol"},{"key":"4822_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/molbev\/msz254","volume":"37","author":"JA Somarelli","year":"2020","unstructured":"Somarelli JA, Boddy AM, Gardner HL, Dewitt SB, Tuohy J, Megquier K et al (2020) Improving cancer drug discovery by studying cancer across the tree of life. Mol Biol Evol 37:11\u201317","journal-title":"Mol Biol Evol"},{"key":"4822_CR9","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.7150\/ijbs.24612","volume":"14","author":"H Xue","year":"2018","unstructured":"Xue H, Li J, Xie H, Wang Y (2018) Review of drug repositioning approaches and resources. Int J Biol Sci 14:1232\u20131244","journal-title":"Int J Biol Sci"},{"key":"4822_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2018","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A et al (2018) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18:41\u201358","journal-title":"Nat Rev Drug Discov"},{"key":"4822_CR11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2147\/DDDT.S46289","volume":"7","author":"M Allarakhia","year":"2013","unstructured":"Allarakhia M (2013) Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases. Drug Des Devel Ther 7:753\u2013766","journal-title":"Drug Des Devel Ther"},{"key":"4822_CR12","doi-asserted-by":"publisher","first-page":"111816","DOI":"10.1016\/j.biopha.2021.111638","volume":"141","author":"HV Sonaye","year":"2021","unstructured":"Sonaye HV, Sheikh RY, Doifode CA (2021) Drug repurposing: iron in the fire for older drugs. Biomed Pharmacother 141:111816","journal-title":"Biomed Pharmacother"},{"key":"4822_CR13","doi-asserted-by":"publisher","first-page":"bbac068","DOI":"10.1093\/bib\/bbac229","volume":"23","author":"TJ Rintala","year":"2022","unstructured":"Rintala TJ, Ghosh A, Fortino V (2022) Network approaches for modeling the effect of drugs and diseases. Brief Bioinform 23:bbac068","journal-title":"Brief Bioinform"},{"key":"4822_CR14","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1177\/1460458220937101","volume":"26","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Che C, Jin B, Zhang N, Su C, Wang F (2020) Knowledge-driven drug repurposing using a comprehensive drug knowledge graph. Health Inf J 26:2737\u20132750","journal-title":"Health Inf J"},{"key":"4822_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12:31\u201346","journal-title":"Cancer Discov"},{"key":"4822_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57\u201370","journal-title":"Cell"},{"key":"4822_CR17","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674","journal-title":"Cell"},{"key":"4822_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-018-0782-4","volume":"17","author":"Z Du","year":"2018","unstructured":"Du Z, Lovly CM (2018) Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer 17:41","journal-title":"Mol Cancer"},{"key":"4822_CR19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41392-022-01244-z","volume":"8","author":"V Panwar","year":"2023","unstructured":"Panwar V, Singh A, Bhatt M, Tonk RK, Azizov S, Raza AS et al (2023) Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Ther 8:19","journal-title":"Signal Transduct Target Ther"},{"key":"4822_CR20","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","volume":"36","author":"T Zhan","year":"2017","unstructured":"Zhan T, Rindtorff N, Boutros M (2017) Wnt signaling in cancer. Oncogene 36:1461\u20131473","journal-title":"Oncogene"},{"key":"4822_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0085","volume":"1","author":"VS Rodrik-Outmezguine","year":"2011","unstructured":"Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E et al (2011) mTOR kinase Inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov 1:248\u2013259","journal-title":"Cancer Discov"},{"key":"4822_CR22","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1158\/2159-8290.CD-14-1518","volume":"5","author":"LG Ahronian","year":"2015","unstructured":"Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE et al (2015) Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov 5:358\u2013367","journal-title":"Cancer Discov"},{"key":"4822_CR23","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.tips.2008.07.004","volume":"29","author":"S Krishna","year":"2008","unstructured":"Krishna S, Bustamante L, Haynes RK, Staines HM (2008) Artemisinins: their growing importance in medicine. Trends Pharmacol Sci 29:520\u2013527","journal-title":"Trends Pharmacol Sci"},{"key":"4822_CR24","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2217\/fon.13.228","volume":"10","author":"SK Goodrich","year":"2014","unstructured":"Goodrich SK, Schlegel CR, Wang G, Belinson JL (2014) Use of Artemisinin and its derivatives to treat HPV-infected\/transformed cells and cervical cancer: a review. Future Oncol 10:647\u2013654","journal-title":"Future Oncol"},{"key":"4822_CR25","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/ijc.22804","volume":"121","author":"LN Li","year":"2007","unstructured":"Li LN, Zhang HD, Yuan SJ, Tian ZY, Wang L, Sun ZX (2007) Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt\/\u03b2-catenin pathway. Int J Cancer 121:1360\u20131365","journal-title":"Int J Cancer"},{"key":"4822_CR26","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.3390\/pharmaceutics14020395","volume":"14","author":"X Zhou","year":"2022","unstructured":"Zhou X, Suo F, Haslinger K, Quax WJ (2022) Artemisinin-type drugs in tumor cell death: mechanisms, combination treatment with biologics and nanoparticle delivery. Pharmaceutics 14:1326","journal-title":"Pharmaceutics"},{"key":"4822_CR27","doi-asserted-by":"publisher","first-page":"817","DOI":"10.7150\/thno.67932","volume":"12","author":"Q Zeng","year":"2022","unstructured":"Zeng Q, Ma X, Song Y, Chen Q, Jiao Q, Zhou L (2022) Targeting regulated cell death in tumor nanomedicines. Theranostics 12:817\u2013841","journal-title":"Theranostics"},{"key":"4822_CR28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","volume":"7","author":"F Peng","year":"2022","unstructured":"Peng F, Liao M, Qin R, Zhu S, Peng C, Fu L et al (2022) Regulated cell death (RCD) in cancer: key pathways and targeted therapies. Signal Transduct Target Ther 7:39","journal-title":"Signal Transduct Target Ther"},{"key":"4822_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0099-5428(05)32002-8","volume":"32","author":"BMH Al-Hadiya","year":"2005","unstructured":"Al-Hadiya BMH (2005) Niclosamide: comprehensive profile. Profiles Drug Subst Excip Relat Methodol 32:67\u201396","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"key":"4822_CR30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0306-3623(96)00149-8","volume":"28","author":"GJ Frayha","year":"1997","unstructured":"Frayha GJ, Smyth JD, Gobert JG, Savel J (1997) The mechanisms of action of antiprotozoal and anthelmintic drugs in man. Gen Pharmacol 28:273\u2013299","journal-title":"Gen Pharmacol"},{"key":"4822_CR31","volume-title":"Progress in drug research","year":"2002","unstructured":"Jucker EM (ed) (2002) Progress in drug research. Springer, Basel"},{"key":"4822_CR32","doi-asserted-by":"publisher","first-page":"e85887","DOI":"10.1371\/journal.pone.0085887","volume":"9","author":"T Ye","year":"2014","unstructured":"Ye T, Xiong Y, Yan Y, Xia Y, Song X, Liu L et al (2014) The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model. PLoS ONE 9:e85887","journal-title":"PLoS ONE"},{"key":"4822_CR33","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1038\/bcj.2011.38","volume":"1","author":"FL Khanim","year":"2011","unstructured":"Khanim FL, Merrick BAME, Giles HV, Jankute M, Jackson JB, Giles LJ et al (2011) Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production. Blood Cancer J 1:e39","journal-title":"Blood Cancer J"},{"key":"4822_CR34","doi-asserted-by":"publisher","first-page":"517","DOI":"10.5483\/BMBRep.2011.44.8.517","volume":"44","author":"SJ Park","year":"2011","unstructured":"Park SJ, Shin JH, Kang H, Hwang JJ, Cho DH (2011) Niclosamide induces mitochondria fragmentation and promotes both apoptotic and autophagic cell death. BMB Rep 44:517\u2013522","journal-title":"BMB Rep"},{"key":"4822_CR35","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1158\/0008-5472.CAN-09-3950","volume":"70","author":"Y Jin","year":"2010","unstructured":"Jin Y, Lu Z, Ding K, Li J, Du X, Chen C et al (2010) Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-\u03baB pathway and generation of reactive oxygen species. Cancer Res 70:2516\u20132527","journal-title":"Cancer Res"},{"key":"4822_CR36","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1158\/1535-7163.MCT-12-0002","volume":"11","author":"YT Yo","year":"2012","unstructured":"Yo YT, Lin YW, Wang YC, Balch C, Huang RL, Chan MWY et al (2012) Growth Inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther 11:1703\u20131712","journal-title":"Mol Cancer Ther"},{"key":"4822_CR37","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/s41418-022-01022-y","volume":"29","author":"L Sainero-Alcolado","year":"2022","unstructured":"Sainero-Alcolado L, Lia\u00f1o-Pons J, Ruiz-P\u00e9rez MV, Arsenian-Henriksson M (2022) Targeting mitochondrial metabolism for precision medicine in cancer. Cell Death Differ 29:1304\u20131317","journal-title":"Cell Death Differ"},{"key":"4822_CR38","first-page":"761","volume":"12","author":"L Sun","year":"2009","unstructured":"Sun L, Zhang H, Gao P (2009) Metabolic reprogramming and epigenetic modifications on the path to cancer. Protein Cell 12:761\u2013777","journal-title":"Protein Cell"},{"key":"4822_CR39","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","volume":"34","author":"NN Pavlova","year":"2022","unstructured":"Pavlova NN, Zhu J, Thompson CB (2022) The hallmarks of cancer metabolism: still emerging. Cell Metab 34:355\u2013377","journal-title":"Cell Metab"},{"key":"4822_CR40","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2165\/00003495-200059050-00009","volume":"59","author":"A Prakash","year":"2000","unstructured":"Prakash A, Jarvis B, Chong ASF, Simmonds HA (2000) Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 59:1137\u20131182","journal-title":"Drugs"},{"key":"4822_CR41","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0014-5793(93)81704-4","volume":"334","author":"T Mattar","year":"1993","unstructured":"Mattar T, Kochhar K, Bartlett R, Bremer EG, Finnegan A (1993) Inhibition of the epidermal growth factor receptor tyrosine kinase activity by Leflunomide. FEBS Lett 334:161\u2013164","journal-title":"FEBS Lett"},{"key":"4822_CR42","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1158\/2159-8290.CD-16-0611","volume":"7","author":"KK Brown","year":"2017","unstructured":"Brown KK, Spinelli JB, Asara JM, Toker A (2017) Adaptive reprogramming of de Novo pyrimidine synthesis is a metabolic vulnerability in triple-negative breast cancer. Cancer Discov 7:391\u2013399","journal-title":"Cancer Discov"},{"key":"4822_CR43","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1158\/2159-8290.CD-16-0612","volume":"7","author":"D Mathur","year":"2017","unstructured":"Mathur D, Stratikopoulos E, Ozturk S, Steinbach N, Pegno S, Schoenfeld S et al (2017) PTEN regulates glutamine flux to pyrimidine synthesis and sensitivity to dihydroorotate dehydrogenase Inhibition. Cancer Discov 7:380\u2013390","journal-title":"Cancer Discov"},{"key":"4822_CR44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.32607\/20758251-2013-5-1-85-89","volume":"5","author":"AA Khutornenko","year":"2013","unstructured":"Khutornenko AA, Dalina AA, Chernyak BV, Chumakov PM, Evstafieva AG (2013) The role of dihydroorotate dehydrogenase in apoptosis induction in response to Inhibition of the mitochondrial respiratory chain complex III. Acta Naturae 5:85\u201394","journal-title":"Acta Naturae"},{"key":"4822_CR45","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41419-020-2224-7","volume":"11","author":"S Hubackova","year":"2020","unstructured":"Hubackova S, Davidova E, Boukalova S, Kovarova J, Bajzikova M, Coelho A et al (2020) Replication and ribosomal stress induced by targeting pyrimidine synthesis and cellular checkpoints suppress p53-deficient tumors. Cell Death Dis 11:110","journal-title":"Cell Death Dis"},{"key":"4822_CR46","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1056\/NEJMra072067","volume":"358","author":"M Esteller","year":"2008","unstructured":"Esteller M (2008) Epigenetics in cancer. N Engl J Med 358:1148\u20131159","journal-title":"N Engl J Med"},{"key":"4822_CR47","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1055\/s-0029-1237423","volume":"27","author":"C Dupont","year":"2009","unstructured":"Dupont C, Armant DR, Brenner CA (2009) Epigenetics: definition, mechanisms and clinical perspective. Semin Reprod Med 27:351\u2013357","journal-title":"Semin Reprod Med"},{"key":"4822_CR48","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1101\/gad.1232504","volume":"18","author":"AH Lund","year":"2004","unstructured":"Lund AH, Van Lohuizen M (2004) Epigenetics and cancer. Genes Dev 18:2315\u20132335","journal-title":"Genes Dev"},{"key":"4822_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/carcin\/bgp220","volume":"31","author":"S Sharma","year":"2009","unstructured":"Sharma S, Kelly TK, Jones PA (2009) Epigenetics in cancer. Carcinogenesis 31:27\u201336","journal-title":"Carcinogenesis"},{"key":"4822_CR50","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S1535-6108(02)00102-2","volume":"2","author":"CJ Sherr","year":"2002","unstructured":"Sherr CJ, McCormick F (2002) The RB and p53 pathways in cancer. Cancer Cell 2:103\u2013112","journal-title":"Cancer Cell"},{"key":"4822_CR51","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/ng0894-480","volume":"7","author":"BO Williams","year":"1994","unstructured":"Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T (1994) Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 7:480\u2013484","journal-title":"Nat Genet"},{"key":"4822_CR52","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrc3216","volume":"12","author":"AL Manning","year":"2012","unstructured":"Manning AL, Dyson NJ (2012) RB: mitotic implications of a tumour suppressor. Nat Rev Cancer 12:220\u2013226","journal-title":"Nat Rev Cancer"},{"key":"4822_CR53","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc.2017.109","volume":"18","author":"VJN Bykov","year":"2018","unstructured":"Bykov VJN, Eriksson SE, Bianchi J, Wiman KG (2018) Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer 18:89\u2013102","journal-title":"Nat Rev Cancer"},{"key":"4822_CR54","doi-asserted-by":"publisher","first-page":"e13388","DOI":"10.1111\/eci.13388","volume":"50","author":"N Mohammadzadeh","year":"2020","unstructured":"Mohammadzadeh N, Montecucco F, Carbone F, Xu S, Al-Rasadi K, Sahebkar A (2020) Statins: epidrugs with effects on endothelial health? Eur J Clin Invest 50:e13388","journal-title":"Eur J Clin Invest"},{"key":"4822_CR55","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3389\/fchem.2020.00516","volume":"8","author":"E Di Bello","year":"2020","unstructured":"Di Bello E, Zwergel C, Mai A, Valente S (2020) The innovative potential of Statins in cancer: new targets for new therapies. Front Chem 8:516","journal-title":"Front Chem"},{"key":"4822_CR56","doi-asserted-by":"publisher","first-page":"11314","DOI":"10.1074\/jbc.M110.193714","volume":"286","author":"CC Mandal","year":"2011","unstructured":"Mandal CC, Ghosh-Choudhury N, Yoneda T, Choudhury GG, Ghosh-Choudhury N (2011) Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem 286:11314\u201311327","journal-title":"J Biol Chem"},{"key":"4822_CR57","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3390\/ph15081015","volume":"15","author":"C Miyajima","year":"2022","unstructured":"Miyajima C, Hayakawa Y, Inoue Y, Nagasaka M, Hayashi H (2022) HMG-CoA reductase inhibitor Statins activate the transcriptional activity of p53 by regulating the expression of TAZ. Pharmaceuticals 15:993","journal-title":"Pharmaceuticals"},{"key":"4822_CR58","doi-asserted-by":"publisher","first-page":"e2673","DOI":"10.1038\/cddis.2017.46","volume":"8","author":"J Li","year":"2017","unstructured":"Li J, Liu J, Liang Z, He F, Yang L, Li P et al (2017) Simvastatin and Atorvastatin inhibit DNA replication licensing factor MCM7 and effectively suppress RB-deficient tumors growth. Cell Death Dis 8:e2673","journal-title":"Cell Death Dis"},{"key":"4822_CR59","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10555-019-09808-2","volume":"38","author":"J Mitschke","year":"2019","unstructured":"Mitschke J, Burk UC, Reinheckel T (2019) The role of proteases in epithelial-to-mesenchymal cell transitions in cancer. Cancer Metastasis Rev 38:431\u2013444","journal-title":"Cancer Metastasis Rev"},{"key":"4822_CR60","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/cr.2009.5","volume":"19","author":"J Xu","year":"2009","unstructured":"Xu J, Lamouille S, Derynck R (2009) TGF-\u03b2-induced epithelial to mesenchymal transition. Cell Res 19:156\u2013172","journal-title":"Cell Res"},{"key":"4822_CR61","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/jcp.21223","volume":"213","author":"H Hugo","year":"2007","unstructured":"Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED et al (2007) Epithelial - mesenchymal and mesenchymal - epithelial transitions in carcinoma progression. J Cell Physiol 213:374\u2013383","journal-title":"J Cell Physiol"},{"key":"4822_CR62","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.1158\/1078-0432.CCR-05-2722","volume":"12","author":"TK Lee","year":"2006","unstructured":"Lee TK, Poon RTP, Yuen AP, Ling MT, Kwok WK, Wang XH et al (2006) Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 12:5369\u20135376","journal-title":"Clin Cancer Res"},{"key":"4822_CR63","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/jcp.54.5.391","volume":"54","author":"RT Pirinen","year":"2001","unstructured":"Pirinen RT, Hirvikoski P, Johansson RT, Hollmen S, Kosma VM (2001) Reduced expression of \u03b1-catenin, \u03b2-catenin, and \u03b3-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer. J Clin Pathol 54:391\u2013395","journal-title":"J Clin Pathol"},{"key":"4822_CR64","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc21-S009","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association (2021) 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142021. Diabetes Care 44:S111\u2013S124","journal-title":"Diabetes Care"},{"key":"4822_CR65","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41574-019-0242-2","volume":"15","author":"M Foretz","year":"2019","unstructured":"Foretz M, Guigas B, Viollet B (2019) Understanding the glucoregulatory mechanisms of Metformin in type 2 diabetes mellitus. Nat Rev Endocrinol 15:569\u2013589","journal-title":"Nat Rev Endocrinol"},{"key":"4822_CR66","doi-asserted-by":"publisher","first-page":"682","DOI":"10.7326\/M18-1605","volume":"170","author":"JW Apolzan","year":"2019","unstructured":"Apolzan JW, Venditti EM, Edelstein SL, Knowler WC, Dabelea D, Boyko EJ et al (2019) Long-term weight loss with Metformin or lifestyle intervention in the diabetes prevention program outcomes study. Ann Intern Med 170:682\u2013690","journal-title":"Ann Intern Med"},{"key":"4822_CR67","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577\u20131589","journal-title":"N Engl J Med"},{"key":"4822_CR68","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000481951","volume":"138","author":"ME De Broe","year":"2018","unstructured":"De Broe ME, Kajbaf F, Lalau JD (2018) Renoprotective effects of Metformin. Nephron 138:261\u2013274","journal-title":"Nephron"},{"key":"4822_CR69","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.arr.2017.08.003","volume":"40","author":"JM Campbell","year":"2017","unstructured":"Campbell JM, Bellman SM, Stephenson MD, Lisy K (2017) Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: a systematic review and meta-analysis. Ageing Res Rev 40:31\u201344","journal-title":"Ageing Res Rev"},{"key":"4822_CR70","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrendo.2013.256","volume":"10","author":"I Pernicova","year":"2014","unstructured":"Pernicova I, Korbonits M (2014) Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 10:143\u2013156","journal-title":"Nat Rev Endocrinol"},{"key":"4822_CR71","doi-asserted-by":"publisher","first-page":"40767","DOI":"10.18632\/oncotarget.8194","volume":"7","author":"YK Chae","year":"2016","unstructured":"Chae YK, Arya A, Malecek MK, Shin DS, Carneiro B, Chandra S et al (2016) Repurposing Metformin for cancer treatment: current clinical studies. Oncotarget 7:40767\u201340780","journal-title":"Oncotarget"},{"key":"4822_CR72","doi-asserted-by":"publisher","first-page":"32","DOI":"10.21037\/sci.2017.03.04","volume":"4","author":"MJ Pianko","year":"2017","unstructured":"Pianko MJ, Liu Y, Bagchi S, Lesokhin AM (2017) Immune checkpoint Blockade for hematologic malignancies: a review. Stem Cell Investig 4:32","journal-title":"Stem Cell Investig"},{"key":"4822_CR73","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-020-00947-6","volume":"13","author":"B Salik","year":"2020","unstructured":"Salik B, Smyth MJ, Nakamura K (2020) Targeting immune checkpoints in hematological malignancies. J Hematol Oncol 13:111","journal-title":"J Hematol Oncol"},{"key":"4822_CR74","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s41577-019-0271-z","volume":"20","author":"H Garner","year":"2020","unstructured":"Garner H, de Visser KE (2020) Immune crosstalk in cancer progression and metastatic spread: a complex conversation. Nat Rev Immunol 20:483\u2013497","journal-title":"Nat Rev Immunol"},{"key":"4822_CR75","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","volume":"35","author":"DS Vinay","year":"2015","unstructured":"Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E et al (2015) Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol 35:S185\u2013S198","journal-title":"Semin Cancer Biol"},{"key":"4822_CR76","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science 331:1565\u20131570","journal-title":"Science"},{"key":"4822_CR77","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1002\/j.2040-4603.2020.tb00144.x","volume":"10","author":"J Rubingh","year":"2020","unstructured":"Rubingh J, van der Spek A, Fliers E, Boelen A (2020) The role of thyroid hormone in the innate and adaptive immune response during infection. Compr Physiol 10:1277\u20131287","journal-title":"Compr Physiol"},{"key":"4822_CR78","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.3390\/cancers13215277","volume":"13","author":"MV Deligiorgi","year":"2021","unstructured":"Deligiorgi MV, Sagredou S, Vakkas L, Trafalis DT (2021) The continuum of thyroid disorders related to immune checkpoint inhibitors: still many pending queries. Cancers 13:1970","journal-title":"Cancers"},{"key":"4822_CR79","doi-asserted-by":"publisher","first-page":"354","DOI":"10.33594\/000000025","volume":"52","author":"VA Alamino","year":"2019","unstructured":"Alamino VA, Del Mar Montesinos M, Soler MF, Giusiano L, Gigena N, Fozzatti L et al (2019) Dendritic cells exposed to Triiodothyronine deliver pro-inflammatory signals and amplify IL-17-driven immune responses. Cell Physiol Biochem 52:354\u2013367","journal-title":"Cell Physiol Biochem"},{"key":"4822_CR80","doi-asserted-by":"publisher","first-page":"e000957","DOI":"10.1136\/jitc-2020-000957","volume":"8","author":"JM Chauvin","year":"2020","unstructured":"Chauvin JM, Zarour HM (2020) TIGIT in cancer immunotherapy. J Immunother Cancer 8:e000957","journal-title":"J Immunother Cancer"},{"key":"4822_CR81","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3892\/or.2021.7943","volume":"45","author":"L Liu","year":"2021","unstructured":"Liu L, You X, Han S, Sun Y, Zhang J, Zhang Y (2021) CD155\/TIGIT, a novel immune checkpoint in human cancers (Review). Oncol Rep 45:835\u2013845","journal-title":"Oncol Rep"},{"key":"4822_CR82","doi-asserted-by":"publisher","first-page":"699895","DOI":"10.3389\/fimmu.2021.699895","volume":"12","author":"Z Ge","year":"2021","unstructured":"Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J (2021) TIGIT, the next step towards successful combination immune checkpoint therapy in cancer. Front Immunol 12:699895","journal-title":"Front Immunol"},{"key":"4822_CR83","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12964-020-00638-2","volume":"18","author":"X Zhou","year":"2020","unstructured":"Zhou X, Du J, Wang H, Chen C, Jiao L, Cheng X et al (2020) Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT\/PVR. Cell Commun Signal 18:142","journal-title":"Cell Commun Signal"},{"key":"4822_CR84","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/10799893.2020.1839765","volume":"42","author":"N Pourzardosht","year":"2022","unstructured":"Pourzardosht N, Hashemi ZS, Mard-Soltani M, Jahangiri A, Rahbar MR, Zakeri A et al (2022) Liothyronine could block the programmed death-ligand 1 (PDL1) activity: an e-Pharmacophore modeling and virtual screening study. J Recept Signal Transduct Res 42:34\u201342","journal-title":"J Recept Signal Transduct Res"},{"key":"4822_CR85","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1101\/gad.263863.115","volume":"29","author":"JC Schmidt","year":"2015","unstructured":"Schmidt JC, Cech TR (2015) Human telomerase: biogenesis, trafficking, recruitment, and activation. Genes Dev 29:1095\u20131105","journal-title":"Genes Dev"},{"key":"4822_CR86","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1007\/s11033-010-0439-x","volume":"38","author":"A Wojtyla","year":"2011","unstructured":"Wojtyla A, Gladych M, Rubis B (2011) Human telomerase activity regulation. Mol Biol Rep 38:3339\u20133349","journal-title":"Mol Biol Rep"},{"key":"4822_CR87","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41580-020-0234-z","volume":"21","author":"CM Roake","year":"2020","unstructured":"Roake CM, Artandi SE (2020) Regulation of human telomerase in homeostasis and disease. Nat Rev Mol Cell Biol 21:384\u2013397","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4822_CR88","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41568-022-00490-1","volume":"22","author":"J Gao","year":"2022","unstructured":"Gao J, Pickett HA (2022) Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies. Nat Rev Cancer 22:515\u2013532","journal-title":"Nat Rev Cancer"},{"key":"4822_CR89","doi-asserted-by":"publisher","first-page":"115071","DOI":"10.1016\/j.ejmech.2023.115121","volume":"249","author":"K Vishwakarma","year":"2023","unstructured":"Vishwakarma K, Dey R, Bhatt H (2023) Telomerase: a prominent oncological target for development of chemotherapeutic agents. Eur J Med Chem 249:115071","journal-title":"Eur J Med Chem"},{"key":"4822_CR90","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.tibs.2013.07.001","volume":"38","author":"KC Low","year":"2013","unstructured":"Low KC, Tergaonkar V (2013) Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem Sci 38:426\u2013434","journal-title":"Trends Biochem Sci"},{"key":"4822_CR91","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/0008-5472.CAN-13-3568","volume":"74","author":"Y Li","year":"2014","unstructured":"Li Y, Tergaonkar V (2014) Noncanonical functions of telomerase: implications in telomerase-targeted cancer therapies. Cancer Res 74:1639\u20131644","journal-title":"Cancer Res"},{"key":"4822_CR92","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1038\/s41388-019-0872-9","volume":"38","author":"X Yuan","year":"2019","unstructured":"Yuan X, Larsson C, Xu D (2019) Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Oncogene 38:6172\u20136183","journal-title":"Oncogene"},{"key":"4822_CR93","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41419-023-06376-w","volume":"15","author":"M Liu","year":"2024","unstructured":"Liu M, Zhang Y, Jian Y, Gu L, Zhang D, Zhou H et al (2024) The regulations of telomerase reverse transcriptase (TERT) in cancer. Cell Death Dis 15:12","journal-title":"Cell Death Dis"},{"key":"4822_CR94","doi-asserted-by":"publisher","first-page":"101651","DOI":"10.1016\/j.dnarep.2019.102651","volume":"81","author":"Y Wang","year":"2019","unstructured":"Wang Y, Luo W, Wang Y (2019) PARP-1 and its associated nucleases in DNA damage response. DNA Repair 81:101651","journal-title":"DNA Repair"},{"key":"4822_CR95","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1038\/s41467-019-10741-9","volume":"10","author":"MC Caron","year":"2019","unstructured":"Caron MC, Sharma AK, O\u2019Sullivan J, Myler LR, Ferreira MT, Rodrigue A et al (2019) Poly(ADP-ribose) polymerase-1 antagonizes DNA resection at double-strand breaks. Nat Commun 10:2954","journal-title":"Nat Commun"},{"key":"4822_CR96","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A (2017) PARP inhibitors: synthetic lethality in the clinic. Science 355:1152\u20131158","journal-title":"Science"},{"key":"4822_CR97","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41467-018-03159-2","volume":"9","author":"GE Ronson","year":"2018","unstructured":"Ronson GE, Piberger AL, Higgs MR, Olsen AL, Stewart GS, McHugh PJ et al (2018) PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation. Nat Commun 9:746","journal-title":"Nat Commun"},{"key":"4822_CR98","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","volume":"18","author":"A Ray Chaudhuri","year":"2017","unstructured":"Ray Chaudhuri A, Nussenzweig A (2017) The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol 18:610\u2013621","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4822_CR99","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1158\/0008-5472.CAN-17-2269","volume":"78","author":"J Mukherjee","year":"2018","unstructured":"Mukherjee J, Johannessen TC, Ohba S, Chow TT, Jones L, Pandita A et al (2018) Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere phenotype in glioma. Cancer Res 78:2966\u20132977","journal-title":"Cancer Res"},{"key":"4822_CR100","doi-asserted-by":"publisher","first-page":"671298","DOI":"10.3389\/fphar.2021.777663","volume":"12","author":"K Wu","year":"2021","unstructured":"Wu K, Liang J, Shao Y, Xiong S, Feng S, Li X (2021) Evaluation of the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Front Pharmacol 12:671298","journal-title":"Front Pharmacol"},{"key":"4822_CR101","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.3390\/cancers14040897","volume":"14","author":"DR Principe","year":"2022","unstructured":"Principe DR (2022) Precision medicine for BRCA\/PALB2-mutated pancreatic cancer and emerging strategies to improve therapeutic responses to PARP Inhibition. Cancers 14:2083","journal-title":"Cancers"},{"key":"4822_CR102","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","volume":"86","author":"D Hanahan","year":"1996","unstructured":"Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353\u2013364","journal-title":"Cell"},{"key":"4822_CR103","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592\u2013603","journal-title":"Nat Rev Cancer"},{"key":"4822_CR104","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1084\/jem.133.2.275","volume":"133","author":"J Folkman","year":"1971","unstructured":"Folkman J, Merler E, Abernathy C, Williams G (1971) Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133:275\u2013288","journal-title":"J Exp Med"},{"key":"4822_CR105","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342","journal-title":"N Engl J Med"},{"key":"4822_CR106","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41571-019-0181-9","volume":"16","author":"EA Kuczynski","year":"2019","unstructured":"Kuczynski EA, Vermeulen PB, Pezzella F, Kerbel RS, Reynolds AR (2019) Vessel co-option in cancer. Nat Rev Clin Oncol 16:469\u2013493","journal-title":"Nat Rev Clin Oncol"},{"key":"4822_CR107","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ccr.2010.02.027","volume":"17","author":"J Kim","year":"2010","unstructured":"Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV et al (2010) Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 17:388\u2013399","journal-title":"Cancer Cell"},{"key":"4822_CR108","doi-asserted-by":"crossref","first-page":"27","DOI":"10.21037\/tbcr-22-2","volume":"4","author":"Y Wang","year":"2015","unstructured":"Wang Y, Yao Y, Liu H, Ma X, Lv T, Yuan D et al (2015) Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice. Transl Lung Cancer Res 4:27\u201335","journal-title":"Transl Lung Cancer Res"},{"key":"4822_CR109","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1200\/JCO.2013.49.9525","volume":"32","author":"DJ Kim","year":"2014","unstructured":"Kim DJ, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K et al (2014) Open-label, exploratory phase II trial of oral Itraconazole for the treatment of basal cell carcinoma. J Clin Oncol 32:745\u2013751","journal-title":"J Clin Oncol"},{"key":"4822_CR110","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3332\/ecancer.2015.521","volume":"9","author":"P Pantziarka","year":"2015","unstructured":"Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP (2015) Repurposing drugs in oncology (ReDO) - itraconazole as an anti-cancer agent. Ecancermedicalscience 9:521","journal-title":"Ecancermedicalscience"},{"key":"4822_CR111","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1177\/1078155215572931","volume":"22","author":"NR Lockhart","year":"2016","unstructured":"Lockhart NR, Waddell JA, Schrock NE (2016) Itraconazole therapy in a pancreatic adenocarcinoma patient: a case report. J Oncol Pharm Pract 22:528\u2013532","journal-title":"J Oncol Pharm Pract"},{"key":"4822_CR112","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.semcancer.2004.06.006","volume":"14","author":"M Philip","year":"2004","unstructured":"Philip M, Rowley DA, Schreiber H (2004) Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 14:433\u2013439","journal-title":"Semin Cancer Biol"},{"key":"4822_CR113","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4255\/mcpharmacol.09.05","volume":"1","author":"ER Rayburn","year":"2009","unstructured":"Rayburn ER, Ezell SJ, Zhang R (2009) Anti-inflammatory agents for cancer therapy. Mol Cell Pharmacol 1:29\u201343","journal-title":"Mol Cell Pharmacol"},{"key":"4822_CR114","doi-asserted-by":"publisher","first-page":"6429","DOI":"10.1158\/0008-5472.CAN-17-1662","volume":"77","author":"Y Guo","year":"2017","unstructured":"Guo Y, Nie Q, MacLean AL, Li Y, Lei J, Li S (2017) Multiscale modeling of inflammation-induced tumorigenesis reveals competing oncogenic and oncoprotective roles for inflammation. Cancer Res 77:6429\u20136441","journal-title":"Cancer Res"},{"key":"4822_CR115","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.mehy.2005.11.044","volume":"66","author":"MC Salman","year":"2006","unstructured":"Salman MC, Ayhan A (2006) Use of anti-thrombotic agents during chemotherapy for epithelial ovarian cancer. Med Hypotheses 66:1179\u20131181","journal-title":"Med Hypotheses"},{"key":"4822_CR116","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2174\/1568010053622975","volume":"4","author":"Y Monnier","year":"2005","unstructured":"Monnier Y, Zaric J, R\u00fcegg C (2005) Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: from the bench to the bedside and back. Curr Drug Targets Inflamm Allergy 4:31\u201338","journal-title":"Curr Drug Targets Inflamm Allergy"},{"key":"4822_CR117","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1470-2045(07)70146-8","volume":"8","author":"C Gridelli","year":"2007","unstructured":"Gridelli C, Gallo C, Ceribelli A, Gebbia V, Gamucci T, Ciardiello F et al (2007) Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol 8:500\u2013512","journal-title":"Lancet Oncol"},{"key":"4822_CR118","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.canlet.2005.10.030","volume":"242","author":"J Wang","year":"2006","unstructured":"Wang J, Wu K, Bai F, Zhai H, Xie H, Du Y et al (2006) Celecoxib could reverse the hypoxia-induced Angiopoietin-2 upregulation in gastric cancer. Cancer Lett 242:20\u201327","journal-title":"Cancer Lett"},{"key":"4822_CR119","doi-asserted-by":"publisher","first-page":"105610","DOI":"10.1016\/j.biocel.2019.105610","volume":"116","author":"XM Lin","year":"2019","unstructured":"Lin XM, Li S, Zhou C, Li RZ, Wang H, Luo W et al (2019) Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer. Int J Biochem Cell Biol 116:105610","journal-title":"Int J Biochem Cell Biol"},{"key":"4822_CR120","doi-asserted-by":"publisher","first-page":"a000141","DOI":"10.1101\/cshperspect.a000141","volume":"1","author":"M Karin","year":"2009","unstructured":"Karin M (2009) NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 1:a000141","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"4822_CR121","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.it.2022.07.004","volume":"43","author":"D Capece","year":"2022","unstructured":"Capece D, Verzella D, Flati I, Arboretto P, Cornice J, Franzoso G (2022) NF-\u03baB: blending metabolism, immunity, and inflammation. Trends Immunol 43:757\u2013775","journal-title":"Trends Immunol"},{"key":"4822_CR122","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jpha.2021.07.002","volume":"12","author":"A Chauhan","year":"2022","unstructured":"Chauhan A, Islam AU, Prakash H, Singh S (2022) Phytochemicals targeting NF-\u03baB signaling: potential anti-cancer interventions. J Pharm Anal 12:394\u2013405","journal-title":"J Pharm Anal"},{"key":"4822_CR123","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12964-020-00601-1","volume":"18","author":"E Vergani","year":"2020","unstructured":"Vergani E, Dugo M, Cossa M, Frigerio S, Di Guardo L, Gallino G et al (2020) MiR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators. Cell Commun Signal 18:156","journal-title":"Cell Commun Signal"},{"key":"4822_CR124","doi-asserted-by":"publisher","first-page":"20624","DOI":"10.1039\/C9RA00429G","volume":"9","author":"C Zhang","year":"2019","unstructured":"Zhang C, Zhou J, Hu J, Lei S, Yuan M, Chen L et al (2019) Celecoxib attenuates hepatocellular proliferative capacity during hepatocarcinogenesis by modulating a PTEN\/NF-\u03baB\/PRL-3 pathway. RSC Adv 9:20624\u201320632","journal-title":"RSC Adv"},{"key":"4822_CR125","doi-asserted-by":"publisher","first-page":"e16234","DOI":"10.1097\/MD.0000000000016234","volume":"98","author":"Q Guo","year":"2019","unstructured":"Guo Q, Li Q, Wang J, Liu M, Wang Y, Chen Z et al (2019) A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: a preliminary, three-center, clinical trial study. Med (Baltim) 98:e16234","journal-title":"Med (Baltim)"},{"key":"4822_CR126","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.cell.2017.05.015","volume":"169","author":"S He","year":"2017","unstructured":"He S, Sharpless NE (2017) Senescence in health and disease. Cell 169:1000\u20131011","journal-title":"Cell"},{"key":"4822_CR127","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/0014-4827(61)90192-6","volume":"25","author":"L Hayflick","year":"1961","unstructured":"Hayflick L, Moorhead PS (1961) The serial cultivation of human diploid cell strains. Exp Cell Res 25:585\u2013621","journal-title":"Exp Cell Res"},{"key":"4822_CR128","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.cell.2019.10.005","volume":"179","author":"V Gorgoulis","year":"2019","unstructured":"Gorgoulis V, Adams PD, Alimonti A, Bennett DC, Bischof O, Bishop C et al (2019) Cellular senescence: defining a path forward. Cell 179:813\u2013827","journal-title":"Cell"},{"key":"4822_CR129","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1159\/000444877","volume":"62","author":"MC Velarde","year":"2016","unstructured":"Velarde MC, Demaria M (2016) Targeting senescent cells: possible implications for delaying skin aging: a mini-review. Gerontology 62:513\u2013518","journal-title":"Gerontology"},{"key":"4822_CR130","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.pharmthera.2018.08.006","volume":"193","author":"V Myrianthopoulos","year":"2019","unstructured":"Myrianthopoulos V, Evangelou K, Vasileiou PVS, Cooks T, Vassilakopoulos TP, Pangalis GA et al (2019) Senescence and senotherapeutics: a new field in cancer therapy. Pharmacol Ther 193:31\u201349","journal-title":"Pharmacol Ther"},{"key":"4822_CR131","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/jnci\/djq364","volume":"102","author":"JA Ewald","year":"2010","unstructured":"Ewald JA, Desotelle JA, Wilding G, Jarrard DF (2010) Therapy-induced senescence in cancer. J Natl Cancer Inst 102:1536\u20131546","journal-title":"J Natl Cancer Inst"},{"key":"4822_CR132","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/nm.4000","volume":"21","author":"BG Childs","year":"2015","unstructured":"Childs BG, Durik M, Baker DJ, Van Deursen JM (2015) Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med 21:1424\u20131435","journal-title":"Nat Med"},{"key":"4822_CR133","doi-asserted-by":"publisher","first-page":"955","DOI":"10.18632\/aging.101202","volume":"9","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, Doornebal EJ, Pirtskhalava T, Giorgadze N, Wentworth M, Fuhrmann-Stroissnigg H, Niedernhofer LJ, Robbins PD, Tchkonia T, Kirkland JL (2017) New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging 9:955\u2013963","journal-title":"Aging"},{"key":"4822_CR134","doi-asserted-by":"publisher","first-page":"11190","DOI":"10.1038\/ncomms11190","volume":"7","author":"R Yosef","year":"2016","unstructured":"Yosef R, Pilpel N, Tokarsky-Amiel R, Biran A, Ovadya Y, Cohen S, Vadai E, Dassa L, Shahar E, Condiotti R, Ben-Porath I, Krizhanovsky V (2016) Directed elimination of senescent cells by Inhibition of BCL-W and BCL-XL. Nat Commun 7:11190","journal-title":"Nat Commun"},{"key":"4822_CR135","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/acel.12445","volume":"15","author":"Y Zhu","year":"2016","unstructured":"Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, Dai HM, Ling YY, Stout MB, Pirtskhalava T, Giorgadze N, Johnson KO, Giles CB, Wren JD, Niedernhofer LJ, Robbins PD, Kirkland JL (2016) Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell 15:428\u2013435","journal-title":"Aging Cell"},{"key":"4822_CR136","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.celrep.2017.09.085","volume":"21","author":"L Wang","year":"2017","unstructured":"Wang L, Leite de Oliveira R, Wang C, Fernandes Neto JM, Mainardi S, Evers B, Lieftink C, Morris B, Jochems F, Willemsen L, Beijersbergen RL, Bernards R (2017) High-Throughput functional genetic and compound screens identify targets for senescence induction in cancer. Cell Rep 21:773\u2013783","journal-title":"Cell Rep"},{"key":"4822_CR137","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41467-017-00314-z","volume":"8","author":"H Fuhrmann-Stroissnigg","year":"2017","unstructured":"Fuhrmann-Stroissnigg H, Ling YY, Zhao J, McGowan SJ, Zhu Y, Brooks RW, Grassi D, Gregg SQ, Stripay JL, Dorronsoro A, Corbo L, Tang P, Bukata C, Ring N, Giacca M, Li X, Tchkonia T, Kirkland JL, Niedernhofer LJ, Robbins PD (2017) Identification of HSP90 inhibitors as a novel class of senolytics. Nat Commun 8:422","journal-title":"Nat Commun"},{"key":"4822_CR138","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.trecan.2017.04.008","volume":"3","author":"A Gandalovi\u010dov\u00e1","year":"2017","unstructured":"Gandalovi\u010dov\u00e1 A, Rosel D, Fernandes M, Vesel\u00fd P, Heneberg P, \u010cerm\u00e1k V, Petru\u017eelka L, Kumar S, Sanz-Moreno V, Br\u00e1bek J (2017) Migrastatics\u2014Anti-metastatic and Anti-invasion drugs: promises and challenges. Trends Cancer 3:391\u2013406","journal-title":"Trends Cancer"},{"key":"4822_CR139","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/path.5225","volume":"247","author":"GA Conlon","year":"2019","unstructured":"Conlon GA, Murray GI (2019) Recent advances in Understanding the roles of matrix metalloproteinases in tumour invasion and metastasis. J Pathol 247:629\u2013640","journal-title":"J Pathol"},{"key":"4822_CR140","doi-asserted-by":"publisher","first-page":"9423907","DOI":"10.1155\/2019\/9423907","volume":"2019","author":"C Scheau","year":"2019","unstructured":"Scheau C, Badarau IA, Costache R, Caruntu C, Mihai GL, Didilescu AC, Constantin C, Neagu M (2019) The role of matrix metalloproteinases in the epithelial-mesenchymal transition of hepatocellular carcinoma. Anal Cell Pathol 2019:9423907","journal-title":"Anal Cell Pathol"},{"key":"4822_CR141","doi-asserted-by":"publisher","first-page":"19143","DOI":"10.1016\/S0021-9258(17)46745-7","volume":"268","author":"JG Lyons","year":"1993","unstructured":"Lyons JG, Birkedal-Hansen B, Pierson MC, Whitelock JM, Birkedal-Hansen H (1993) Interleukin-1 and transforming growth factor-\u03b1\/Epidermal growth factor induce expression of Mr 95,000 type IV collagenase\/Gelatinase and interstitial Fibroblast-type collagenase by rat mucosal keratinocytes. J Biol Chem 268:19143\u201319151","journal-title":"J Biol Chem"},{"key":"4822_CR142","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1080\/10715762.2019.1675874","volume":"53","author":"T Kamiya","year":"2019","unstructured":"Kamiya T, Tanaka M, Hara H, Yamaguchi E, Itoh A, Adachi T (2019) Inhibitory effects of 4-hydroperoxy-2-decenoic acid Ethyl ester on phorbol ester- and TGF-\u03b21-induced MMPs expression. Free Radic Res 53:1051\u20131059","journal-title":"Free Radic Res"},{"key":"4822_CR143","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1742-4658.2010.07919.x","volume":"278","author":"C Gialeli","year":"2011","unstructured":"Gialeli C, Theocharis AD, Karamanos NK (2011) Roles of matrix metalloproteinases in cancer progression and their Pharmacological targeting. FEBS J 278:16\u201327","journal-title":"FEBS J"},{"key":"4822_CR144","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/sj.onc.1210768","volume":"27","author":"A Safina","year":"2008","unstructured":"Safina A, Ren MQ, Vandette E, Bakin AV (2008) TAK1 is required for TGF-\u03b21-mediated regulation of matrix metalloproteinase-9 and metastasis. Oncogene 27:1198\u20131207","journal-title":"Oncogene"},{"key":"4822_CR145","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/antibiotics6040026","volume":"6","author":"T Idowu","year":"2017","unstructured":"Idowu T, Schweizer F (2017) Ubiquitous nature of fluoroquinolones: the Oscillation between antibacterial and anticancer activities. Antibiotics 6:26","journal-title":"Antibiotics"},{"key":"4822_CR146","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s15010-005-8209-8","volume":"33","author":"A Dalhoff","year":"2005","unstructured":"Dalhoff A (2005) Immunomodulatory activities of fluoroquinolones. Infection 33:55\u201370","journal-title":"Infection"},{"key":"4822_CR147","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fimmu.2016.00123","volume":"7","author":"VK Raker","year":"2016","unstructured":"Raker VK, Becker C, Steinbrink K (2016) The cAMP pathway as therapeutic target in autoimmune and inflammatory diseases. Front Immunol 7:123","journal-title":"Front Immunol"},{"key":"4822_CR148","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0006-2952(98)00265-2","volume":"56","author":"JP Wang","year":"1998","unstructured":"Wang JP, Raung SL, Huang LJ, Kuo SC (1998) Involvement of Cyclic AMP generation in the Inhibition of respiratory burst by 2-Phenyl-4-quinolone (YT-1) in rat neutrophils. Biochem Pharmacol 56:1505\u20131514","journal-title":"Biochem Pharmacol"},{"key":"4822_CR149","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ijc.11457","volume":"107","author":"JF Santib\u00e1\u00f1ez","year":"2003","unstructured":"Santib\u00e1\u00f1ez JF, Olivares D, Guerrero J, Mart\u00ednez J (2003) Cyclic AMP inhibits TGF\u03b21-induced cell-scattering and invasiveness in murine-transformed keratinocytes. Int J Cancer 107:715\u2013720","journal-title":"Int J Cancer"},{"key":"4822_CR150","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1007\/s11064-008-9737-2","volume":"33","author":"SY Lee","year":"2008","unstructured":"Lee SY, Kim HJ, Lee WJ, Joo SH, Jeon SJ, Kim JW, Kim HS, Ahn JO, Han SH, Chang KT, Kim JH, Kang JH (2008) Differential regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by the cyclic-AMP system in lipopolysaccharide-stimulated rat primary astrocytes. Neurochem Res 33:2324\u20132334","journal-title":"Neurochem Res"},{"key":"4822_CR151","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1128\/MCB.26.4.1223-1234.2006","volume":"26","author":"J Zhang","year":"2006","unstructured":"Zhang J, Bui TN, Xiang J, Lin A (2006) Cyclic AMP inhibits p38 activation via CREB-Induced dynein light chain. Mol Cell Biol 26:1223\u20131234","journal-title":"Mol Cell Biol"},{"key":"4822_CR152","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1128\/MCB.24.7.3057-3067.2004","volume":"24","author":"W Cao","year":"2004","unstructured":"Cao W, Daniel KW, Robidoux J, Puigserver P, Medvedev AV, Bai X, Floering LM, Spiegelman BM, Collins S (2004) p38 Mitogen-Activated protein kinase is the central regulator of Cyclic AMP-Dependent transcription of the brown fat uncoupling protein 1 gene. Mol Cell Biol 24:3057\u20133067","journal-title":"Mol Cell Biol"},{"key":"4822_CR153","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1046\/j.1471-4159.2000.0751870.x","volume":"75","author":"TVO Hansen","year":"2000","unstructured":"Hansen TVO, Rehfeld JF, Nielsen FC (2000) Cyclic AMP-Induced neuronal differentiation via activation of p38 Mitogen-Activated protein kinase. J Neurochem 75:1870\u20131877","journal-title":"J Neurochem"},{"key":"4822_CR154","doi-asserted-by":"publisher","first-page":"e00470","DOI":"10.1128\/MCB.00554-18","volume":"39","author":"H Ma","year":"2019","unstructured":"Ma H, Liu Z, Zhong CQ, Liu Y, Zhang Z, Liang Y, Ye T, Han J, Lu WG, Xu GH, Li M, Liu Q, Xu F, Wang S, Bo X, Zhou Y, Chen Q, Shen Q, Meng ZX (2019) Inactivation of Cyclic AMP response element transcription caused by constitutive p38 activation is mediated by Hyperphosphorylation-Dependent CRTC2 nucleocytoplasmic transport. Mol Cell Biol 39:e00470\u2013e00418","journal-title":"Mol Cell Biol"},{"issue":"21","key":"4822_CR155","doi-asserted-by":"publisher","first-page":"11602","DOI":"10.3390\/ijms222111602","volume":"22","author":"CY Huang","year":"2021","unstructured":"Huang CY, Yang JL, Chen JJ, Tai SB, Yeh YH, Liu PF, Lin MW, Chung CL, Chen CL (2021) Fluoroquinolones suppress TGF-\u03b2- and PMA-induced MMP-9 production in cancer cells: implications in repurposing quinolone antibiotics for cancer treatment. Int J Mol Sci 22(21):11602. https:\/\/doi.org\/10.3390\/ijms222111602","journal-title":"Int J Mol Sci"},{"key":"4822_CR156","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrc745","volume":"2","author":"M Egeblad","year":"2002","unstructured":"Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161\u2013174","journal-title":"Nat Rev Cancer"},{"key":"4822_CR157","first-page":"2894","volume":"8","author":"G Choe","year":"2002","unstructured":"Choe G, Park JK, Jouben-Steele L, Kremen TJ, Liau LM, Vinters HV, McDermott MW, Prados MD, Cloughesy TF, Filho PT, Weiss MH, Nelson SF, Berger MS (2002) Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res 8:2894\u20132901","journal-title":"Clin Cancer Res"},{"key":"4822_CR158","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1006\/jsre.2001.6150","volume":"98","author":"X Yang","year":"2001","unstructured":"Yang X, Staren ED, Howard JM, Iwamura T, Bartsch JE, Appert HE (2001) Invasiveness and MMP expression pancreatic carcinoma. J Surg Res 98:33\u201339","journal-title":"J Surg Res"},{"key":"4822_CR159","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jso.10134","volume":"81","author":"T Suzuki","year":"2002","unstructured":"Suzuki T, Kuwabara Y, Iwata H, Mitani M, Shinoda N, Sato A, Iwa Y, Yashima K, Yamada H (2002) Role of matrix metalloproteinase-9 in in vitro invasion of esophageal carcinoma cells. J Surg Oncol 81:80\u201386","journal-title":"J Surg Oncol"},{"key":"4822_CR160","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/02841860260088845","volume":"41","author":"H Ishimaru","year":"2002","unstructured":"Ishimaru H, Kageyama Y, Hayashi T, Nemoto T, Eishi Y, Kihara K (2002) Expression of matrix metalloproteinase-9 and bombesin\/gastrin-releasing peptide in human prostate cancers and their lymph node metastases. Acta Oncol 41:289\u2013296","journal-title":"Acta Oncol"},{"key":"4822_CR161","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1006\/jsre.2002.6452","volume":"108","author":"D Albo","year":"2002","unstructured":"Albo D, Shinohara T, Tuszynski GP (2002) Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer. J Surg Res 108:51\u201360","journal-title":"J Surg Res"},{"key":"4822_CR162","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/ijc.11037","volume":"105","author":"I Kalembeyi","year":"2003","unstructured":"Kalembeyi I, Inada H, Nishiura R, Imanaka-Yoshida K, Sakakura T, Yoshida T (2003) Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor \u03b21. Int J Cancer 105:53\u201360","journal-title":"Int J Cancer"},{"key":"4822_CR163","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMra0804615","volume":"361","author":"JHJ Hoeijmakers","year":"2009","unstructured":"Hoeijmakers JHJ (2009) DNA Damage, Aging, and cancer. N Engl J Med 361:1475\u20131485","journal-title":"N Engl J Med"},{"key":"4822_CR164","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.3390\/genes12111763","volume":"12","author":"M Ishiai","year":"2021","unstructured":"Ishiai M (2021) Regulation of the Fanconi anemia DNA repair pathway by phosphorylation and monoubiquitination. Genes 12:1742","journal-title":"Genes"},{"key":"4822_CR165","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08467","volume":"461","author":"SP Jackson","year":"2009","unstructured":"Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature 461:1071\u20131078","journal-title":"Nature"},{"key":"4822_CR166","doi-asserted-by":"publisher","first-page":"a000745","DOI":"10.1101\/cshperspect.a000745","volume":"3","author":"G Giglia-Mari","year":"2011","unstructured":"Giglia-Mari G, Zotter A, Vermeulen W (2011) DNA damage response. Cold Spring Harb Perspect Biol 3:a000745","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"4822_CR167","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2014.12.038","volume":"358","author":"H Tian","year":"2015","unstructured":"Tian H, Gao Z, Li HZ, Zhang BF, Wang G, Zhang Q, Pei DS, Zheng JN (2015) DNA damage response - A double-edged sword in cancer prevention and cancer therapy. Cancer Lett 358:8\u201316","journal-title":"Cancer Lett"},{"key":"4822_CR168","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/clc.20324","volume":"31","author":"A Struthers","year":"2008","unstructured":"Struthers A, Krum H, Williams GH (2008) A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 31:153\u2013158","journal-title":"Clin Cardiol"},{"key":"4822_CR169","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/IBPC.S13783","volume":"6","author":"JW Funder","year":"2013","unstructured":"Funder JW (2013) Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. Integr Blood Press Control 6:129\u2013137","journal-title":"Integr Blood Press Control"},{"key":"4822_CR170","doi-asserted-by":"publisher","first-page":"5689","DOI":"10.1093\/nar\/gku217","volume":"42","author":"OD Shahar","year":"2014","unstructured":"Shahar OD, Kalousi A, Eini L, Fisher B, Weiss A, Darr J, Mazina O, Bramson S, Kupiec M, Eden A, Meshorer E, Mazin AV, Brino L, Goldberg M, Livneh Z (2014) A high-throughput chemical screen with FDA approved drugs reveals that the antihypertensive drug spironolactone impairs cancer cell survival by inhibiting homology directed repair. Nucleic Acids Res 42:5689\u20135701","journal-title":"Nucleic Acids Res"},{"key":"4822_CR171","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.chembiol.2013.12.014","volume":"21","author":"S Alekseev","year":"2014","unstructured":"Alekseev S, Ayadi M, Brino L, Egly JM, Larsen AK, Coin F (2014) A small molecule screen identifies an inhibitor of DNA repair inducing the degradation of TFIIH and the chemosensitization of tumor cells to platinum. Chem Biol 21:398\u2013407","journal-title":"Chem Biol"},{"key":"4822_CR172","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1038\/s41388-018-0654-9","volume":"38","author":"A Gold","year":"2019","unstructured":"Gold A, Eini L, Nissim-Rafinia M, Viner R, Ezer S, Erez K, Stelzer G, Zeisel A, Amit M, Zucker A, Weissbein U, Yossa-Shmueli E, Ben-Baruch G, Amit A, Aqeilan RI, Orly J, Marquez N, Zaretsky M, Alpern E, Peri S, Mozes T, Safadi H, Goldberg M, Hornstein E, Livneh E, Sharan R, Benvenisty N, Meshorer E (2019) Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage response. Oncogene 38:3103\u20133118","journal-title":"Oncogene"},{"key":"4822_CR173","doi-asserted-by":"publisher","first-page":"9033","DOI":"10.3390\/ijms23010488","volume":"23","author":"A Sevcikova","year":"2022","unstructured":"Sevcikova A, Izoldova N, Stevurkova V, Kasperova B, Chovanec M, Ciernikova S, Mego M (2022) The impact of the Microbiome on resistance to cancer treatment with chemotherapeutic agents and immunotherapy. Int J Mol Sci 23:9033","journal-title":"Int J Mol Sci"},{"key":"4822_CR174","first-page":"1564","volume":"186","author":"S Gerstberger","year":"2023","unstructured":"Gerstberger S, Jiang Q, Ganesh K (2023) Metastasis Cell 186:1564\u20131579","journal-title":"Metastasis Cell"},{"key":"4822_CR175","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1158\/2159-8290.CD-21-0010","volume":"11","author":"J Massagu\u00e9","year":"2021","unstructured":"Massagu\u00e9 J, Ganesh K (2021) Metastasis-initiating cells and ecosystems. Cancer Discov 11:971\u2013994","journal-title":"Cancer Discov"},{"key":"4822_CR176","doi-asserted-by":"publisher","first-page":"976137","DOI":"10.3389\/fimmu.2022.1051987","volume":"13","author":"F Gao","year":"2022","unstructured":"Gao F, Yu B, Rao B, Sun Y, Yu J, Wang D, Yang B, Chen Z (2022) The effect of the intratumoral Microbiome on tumor occurrence, progression, prognosis and treatment. Front Immunol 13:976137","journal-title":"Front Immunol"},{"key":"4822_CR177","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41586-022-05435-0","volume":"611","author":"JL Galeano Ni\u00f1o","year":"2022","unstructured":"Galeano Ni\u00f1o JL, Wu H, LaCourse KD, Kempchinsky AG, Baryiames A, Barber B, Oxman E, Sa JK, Meyerson M, Aguet F, Haber DA, Chung DC, Adalsteinsson VA, Sarkis J, Stachler MD, Marchini JL, Berthet R, Liggitt D, Barbie DA, Xavier RJ (2022) Effect of the intratumoral microbiota on Spatial and cellular heterogeneity in cancer. Nature 611:810\u2013817","journal-title":"Nature"},{"key":"4822_CR178","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3390\/cancers15041179","volume":"15","author":"J Liu","year":"2023","unstructured":"Liu J, Luo F, Wen L, Zhao Z, Sun H (2023) Current Understanding of microbiomes in cancer metastasis. Cancers 15:1179","journal-title":"Cancers"},{"key":"4822_CR179","doi-asserted-by":"publisher","first-page":"176","DOI":"10.4161\/gmic.20288","volume":"3","author":"P Hofman","year":"2012","unstructured":"Hofman P, Vouret-Craviari V (2012) Microbes-induced EMT at the crossroad of inflammation and cancer. Gut Microbes 3:176\u2013185","journal-title":"Gut Microbes"},{"key":"4822_CR180","doi-asserted-by":"publisher","first-page":"1096774","DOI":"10.3389\/fcimb.2023.1098420","volume":"13","author":"LT Caven","year":"2023","unstructured":"Caven LT, Brinkworth AJ, Carabeo RA (2023) Chlamydia trachomatis induces the transcriptional activity of host YAP in a Hippo-independent fashion. Front Cell Infect Microbiol 13:1096774","journal-title":"Front Cell Infect Microbiol"},{"key":"4822_CR181","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.intimp.2010.12.006","volume":"11","author":"VR Yadav","year":"2011","unstructured":"Yadav VR, Prasad S, Sung B, Aggarwal BB (2011) The role of Chalcones in suppression of NF-\u03baB-mediated inflammation and cancer. Int Immunopharmacol 11:295\u2013309","journal-title":"Int Immunopharmacol"},{"key":"4822_CR182","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/carcin\/12.2.317","volume":"12","author":"S Yamamoto","year":"1991","unstructured":"Yamamoto S, Aizu E, Jiang H, Nakadate T, Kiyoto I, Wang JC, Kato R (1991) The potent anti-tumor-promoting agent Isoliquiritigenin. Carcinogenesis 12:317\u2013323","journal-title":"Carcinogenesis"},{"key":"4822_CR183","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1128\/AAC.01098-15","volume":"59","author":"H Traboulsi","year":"2015","unstructured":"Traboulsi H, Cloutier A, Boyapelly K, Bonin MA, Marsault \u00c9, Cantin AM, Richter MV (2015) The flavonoid Isoliquiritigenin reduces lung inflammation and mouse morbidity during influenza virus infection. Antimicrob Agents Chemother 59:6317\u20136327","journal-title":"Antimicrob Agents Chemother"},{"key":"4822_CR184","first-page":"9577","volume":"8","author":"S Zhao","year":"2015","unstructured":"Zhao S, Chang H, Ma P, Gao G, Jin C, Zhao X, Zhou W, Jin B (2015) Inhibitory effect of DNA topoisomerase inhibitor Isoliquiritigenin on the growth of glioma cells. Int J Clin Exp Pathol 8:9577\u20139582","journal-title":"Int J Clin Exp Pathol"},{"key":"4822_CR185","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.taap.2014.07.001","volume":"279","author":"H Zhao","year":"2014","unstructured":"Zhao H, Zhang X, Chen X, Li Y, Ke Z, Tang T, Chai H, Guo AM, Chen H, Yang J (2014) Isoliquiritigenin, a flavonoid from licorice, blocks M2 macrophage polarization in colitis-associated tumorigenesis through downregulating PGE2 and IL-6. Toxicol Appl Pharmacol 279:311\u2013321","journal-title":"Toxicol Appl Pharmacol"},{"key":"4822_CR186","doi-asserted-by":"publisher","first-page":"85318","DOI":"10.18632\/oncotarget.13347","volume":"7","author":"M Wu","year":"2016","unstructured":"Wu M, Wu Y, Deng B, Li J, Cao H, Qu Y, Qian Z, Zhong G (2016) Isoliquiritigenin decreases the incidence of colitis-associated colorectal cancer by modulating the intestinal microbiota. Oncotarget 7:85318\u201385331","journal-title":"Oncotarget"},{"key":"4822_CR187","first-page":"e1210324","volume":"3","author":"B Thienpont","year":"2016","unstructured":"Thienpont B, Van Dyck L, Lambrechts D (2016) Tumors smother their epigenome. Mol Cell Oncol 3:e1210324","journal-title":"Mol Cell Oncol"},{"key":"4822_CR188","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.12239","volume":"263","author":"M Ko","year":"2015","unstructured":"Ko M, An J, Pastor WA, Koralov SB, Rajewsky K, Rao A (2015) TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunol Rev 263:6\u201321","journal-title":"Immunol Rev"},{"key":"4822_CR189","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.tig.2014.07.005","volume":"30","author":"Y Huang","year":"2014","unstructured":"Huang Y, Rao A (2014) Connections between TET proteins and aberrant DNA modification in cancer. Trends Genet 30:464\u2013474","journal-title":"Trends Genet"},{"key":"4822_CR190","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/leu.2011.134","volume":"25","author":"N Konstandin","year":"2011","unstructured":"Konstandin N, Bultmann S, Szwagierczak A, Dufour A, Ksienzyk B, Schneider F, Herold T, Mulaw M, Kakadia PM, Schneider S, Spiekermann K, Leonhardt H, Bohlander SK (2011) Genomic 5-hydroxymethylcytosine levels correlate with TET2 mutations and a distinct global gene expression pattern in secondary acute myeloid leukemia. Leukemia 25:1649\u20131652","journal-title":"Leukemia"},{"key":"4822_CR191","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nature09586","volume":"468","author":"M Ko","year":"2010","unstructured":"Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, Liu XS, Aravind L, Agarwal S, Maciejewski JP, Rao A (2010) Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468:839\u2013843","journal-title":"Nature"},{"key":"4822_CR192","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1182\/blood-2010-12-324707","volume":"118","author":"E Pronier","year":"2011","unstructured":"Pronier E, Almire C, Mokrani H, Vasanthakumar A, Simon A, Da Costa Reis Monte Mor B, Mass\u00e9 A, Le Cou\u00e9dic JP, Pendino F, Carbonne B, Larghero J, Ravanat JL, Casadevall N, Bernard OA, Droin N, Solary E, Godley LA, Vainchenker W, Plo I, Delhommeau F (2011) Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood 118:2551\u20132555","journal-title":"Blood"},{"key":"4822_CR193","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jep.2014.12.027","volume":"161","author":"B Dinda","year":"2015","unstructured":"Dinda B, Silsarma I, Dinda M, Rudrapaul P (2015) Oroxylum indicum (L.) Kurz, an important Asian traditional medicine: from traditional uses to scientific data for its commercial exploitation. J Ethnopharmacol 161:255\u2013278","journal-title":"J Ethnopharmacol"},{"key":"4822_CR194","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2174\/187152711794480384","volume":"10","author":"K Gasiorowski","year":"2012","unstructured":"Gasiorowski K, Lamer-Zarawska E, Leszek J, Parvathaneni K, Bhushan Yendluri B, Blach-Olszewska Z, Aliev G (2012) Flavones from root of scutellaria baicalensis georgi: drugs of the future in neurodegeneration? CNS Neurol Disord Drug Targets 10:184\u2013191","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"4822_CR195","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1002\/ctm2.577","volume":"11","author":"Y Chen","year":"2021","unstructured":"Chen Y, Zhang J, Zhang M, Song Y, Zhang Y, Fan S, Yao Y, Liu Q, Zhao X, Yang Z, Dong Y (2021) Baicalein resensitizes tamoxifen-resistant breast cancer cells by reducing aerobic Glycolysis and reversing mitochondrial dysfunction via Inhibition of hypoxia\u2010inducible factor\u20101\u03b1. Clin Transl Med 11:e563","journal-title":"Clin Transl Med"},{"key":"4822_CR196","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/ng.3753","volume":"49","author":"OG McDonald","year":"2017","unstructured":"McDonald OG, Li X, Saunders T, Tryggvadottir R, Mentch SJ, Warmoes MO, Word AE, Carrer A, Salz TH, Natsume S, Stauffer KM, Makohon-Moore A, Zhong Y, Wu H, Wellen KE, Locasale JW, Iacobuzio-Donahue CA, Feinberg AP (2017) Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. Nat Genet 49:367\u2013376","journal-title":"Nat Genet"},{"key":"4822_CR197","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.2147\/DDDT.S370114","volume":"16","author":"D Guo","year":"2022","unstructured":"Guo D, Jin J, Liu J, Wang Y, Li D, He Y (2022) Baicalein inhibits the progression and promotes radiosensitivity of esophageal squamous cell carcinoma by targeting HIF-1A. Drug Des Devel Ther 16:2423\u20132436","journal-title":"Drug Des Devel Ther"},{"key":"4822_CR198","first-page":"831","volume":"19","author":"M Shabbir","year":"2008","unstructured":"Shabbir M, Love J, Montgomery B (2008) Phase I trial of PC-Spes2 in advanced hormone refractory prostate cancer. Oncol Rep 19:831\u2013835","journal-title":"Oncol Rep"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04822-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04822-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04822-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:02:15Z","timestamp":1758967335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04822-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":198,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4822"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04822-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,27]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Permission from the Institutional Ethical Committee does not apply to this review article..","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}